UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Post# of 416
(Total Views: 596)
Posted On: 06/13/2019 10:56:40 AM
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
June 10, 2019
ENDONOVO THERAPEUTICS, INC.
Delaware 000-55453 45-2552528
(State or other jurisdiction of incorporation) (Commission File Number)
(IRS Employer Identification No.)
6320 Canoga Avenue, 15th Floor
Woodland Hills, CA 91367 (Address of principal executive office)(Zip Code)
Registrant’s telephone number, including area code: (800) 489-4774
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On June 12, 2019 the Registrant completed its new marketing plan with sales projections. A copy of that plan is an Exhibit to this report.
Item 9.01 Financial Statements and Exhibits.
(a) Financial Statements: None
(b) Exhibits: 99.1 Marketing Plan with sales projections
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 12, 2019
ENDONOVO THERAPEUTICS, INC.
By: /s/ Alan Collier
Alan Collier Chief Executive Officer
Washington, D.C. 20549 FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
June 10, 2019
ENDONOVO THERAPEUTICS, INC.
Delaware 000-55453 45-2552528
(State or other jurisdiction of incorporation) (Commission File Number)
(IRS Employer Identification No.)
6320 Canoga Avenue, 15th Floor
Woodland Hills, CA 91367 (Address of principal executive office)(Zip Code)
Registrant’s telephone number, including area code: (800) 489-4774
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On June 12, 2019 the Registrant completed its new marketing plan with sales projections. A copy of that plan is an Exhibit to this report.
Item 9.01 Financial Statements and Exhibits.
(a) Financial Statements: None
(b) Exhibits: 99.1 Marketing Plan with sales projections
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 12, 2019
ENDONOVO THERAPEUTICS, INC.
By: /s/ Alan Collier
Alan Collier Chief Executive Officer
(1)
(0)Endonovo Therapeutics, Inc. (ENDV) Stock Research Links
WORDS TO LIVE BY:
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.